Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

aTYR PHARMA INC Director's Dealing 2019

Feb 8, 2019

34337_dirs_2019-02-08_5d71744e-fd29-4cc7-ac51-218fa516e52e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2019-02-06

Reporting Person: Krueger Nancy (General Counsel)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 14999 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $17.74 2024-10-10 Common Stock (35608) Direct
Stock Option (right to buy) $9.15 2025-04-17 Common Stock (6286) Direct
Stock Option (right to buy) $14.00 2025-05-06 Common Stock (8800) Direct
Stock Option (right to buy) $10.24 2025-10-01 Common Stock (17000) Direct
Stock Option (right to buy) $6.14 2026-01-27 Common Stock (20000) Direct
Stock Option (right to buy) $3.06 2026-09-13 Common Stock (36500) Direct
Stock Option (right to buy) $3.30 2027-02-07 Common Stock (35000) Direct
Stock Option (right to buy) $3.30 2028-02-06 Common Stock (50000) Direct
Stock Option (right to buy) $0.85 2028-05-16 Common Stock (50000) Direct
Restricted Stock Units $ Common Stock (25000) Direct

Footnotes

F1: The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning November 7, 2014. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

F2: The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning May 17, 2015. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

F3: The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning June 6, 2015. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

F4: The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning November 1, 2015. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

F5: The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning February 1, 2016. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

F6: The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning October 13, 2016. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

F7: The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning March 7, 2017. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

F8: The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning March 6, 2018. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

F9: The shares subject to this option shares vest and become exercisable in 48 monthly installments beginning June 16, 2018. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

F10: The restricted stock units (RSUs) are scheduled to vest in two equal annual installments beginning May 16, 2019, such that this grant will be fully vest on May 16, 2020. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

F11: Each RSU represents a contingent right to receive one share of the Issuer's common stock.